Medine.co.uk

Tetramin 200 Powder Premix For Medicated Feed

Revised: March 2014

AN: 01662/2013


SUMMARY OF PRODUCT CHARACTERISTICS


NAME OF THE VETERINARY MEDICINAL PRODUCT


Tetramin 200 Powder Premix for Medicated Feed


QUALITATIVE AND QUANTITATIVE COMPOSITION


Each kilogram contains 200 g oxytetracycline (as oxytetracycline dihydrate) in a limestone vehicle.


For full list of excipients, see section 6.1.


PHARMACEUTICAL FORM


Premix for medicated feed.

Mid to light brown or light yellow powder premix for incorporation into feedstuffs.


CLINICAL PARTICULARS


Target species


Pigs.


Indications for use, specifying the target species


For use as an aid in the control of respiratory diseases caused by bacteria sensitive to oxytetracycline.


Contraindications


None.


Special warnings for each target species


None.


Special precautions for use


Special precautions for use in animals


Long term use of this product may lead to development of bacterial resistance and is not recommended. However, the recommended course of treatment should be completed.


Special precautions to be taken by the person administering the veterinary medicinal product to animals


If you know you are allergic to oxytetracycline, do not handle the product. When incorporating into feed, care should be taken not to inhale any dust when handling the product and skin contact should be avoided. It is recommended that a face mask, conforming to EN140 with a filter to EN143, be worn during the dispensing of the product. Hands and exposed skin should be washed thoroughly at the end of the operation.


Adverse reactions (frequency and seriousness)

None known.


Use during pregnancy, lactation or lay


Not applicable.


Interaction with other medicinal products and other forms of interaction


The presence of high concentrations of divalent or trivalent ions e.g. Ca2+, may reduce absorption of oxytetracycline due to formation of chelates with no antimicrobial activity. This is only a practical consideration in animals fed milk or milk replacer.


Amounts to be administered and administration route


20 mg/kg bodyweight per day in feed for 15 days.


The following inclusion rates may be used as a guide to obtaining this dose in normal and inappetant pigs.


Food intake expressed as a

percentage of animal bodyweight

Inclusion rate, kg of product per 1000kg of feed

5% (normal)

2 kg

4% (inappetant)

2.5 kg

3% (inappetant)

3.25 kg

2% (inappetant)

5 kg


To ensure thorough dispersion of the product, it should first be mixed with a suitable quantity of feed before incorporation in the final mix. If this product is incorporated in an intermediate feedingstuff, care should be taken to ensure that the intermediate feedingstuff is incorporated at a rate which will yield the same concentration of active ingredient as stated in the dosage schedule.


For incorporation into dry feed at the registered mill.


Overdose (symptoms, emergency procedures, antidotes), if necessary


The safety margin of oxytetracycline in the target species is very wide and toxic signs are unlikely to be seen.


Withdrawal period


Animals must not be slaughtered for human consumption during treatment. Pigs may be slaughtered for human consumption only after 5 days from the end of last treatment.


PHARMACOLOGICAL PROPERTIES


ATCVet Code:QJ01AA06


Oxytetracycline (OTC) is a broad-spectrum antibiotic. Its mode of action is bacteriostatic by inhibition of prokaryotic protein synthesis at the ribosomal level. It is active against Gram-positive and Gram-negative aerobic and anaerobic micro-organisms, Mycoplasmaspp., Chlamydiaspp., Leptospiraspp. and Rickettsias. It has little activity against Salmonellaspp., Escherichia coli, Enterobacter and Klebsiellaspp. and has essentially no activity against Pseudomonasspp., Proteusspp. and yeasts. Sub-Minimum Inhibitory Concentration (MIC) effects have been identified for tetracyclines. Inhibition of adhesion of pathogens to host cell surfaces are known to occur at levels of antibiotic lower than the MIC. Host cell adhesion is an essential pre-requisite for the expression of pathogenicity for several porcine respiratory pathogens e.g. Actinobacillus pleuropneumoniae, Bordetella brochisepticaand mycoplasmas.


Selected resistance to tetracyclines is not uncommon among bacteria and it is important that sensitivity is determined prior to initiation of therapy. Most organisms which are resistant to one member of the tetracycline group will have cross-resistance to other members of the group.


Due to the amphoteric nature of OTC, oral bioavailability is low (<10%). OTC has excellent distribution properties with a Volume of Distribution (Vd) exceeding 1.2 L/kg. The compound tends to concentrate in the lung, liver and kidney. OTC undergoes enterohepatic circulation. It does not appear to be metabolised to any significant degree. The compound is mainly excreted as the parent molecule primarily in the urine but also in the faeces.


PHARMACEUTICAL PARTICULARS


List of excipients


Light Liquid Paraffin

Limestone Flour


Incompatibilities


None.


Shelf life


Shelf life of the veterinary medicinal product as packaged for sale: 4 years.

The product is stable during pelleting and in pelleted and unpelleted feed for up to 3 months and in protein concentrates and vitamin/mineral premixes for 6 months.


Special precautions for storage


Do not store above 25°C. Store in a dry place. Protect from light.


Nature and composition of immediate packaging


Supplied in 2 kg polyester/aluminium foil/polyethylene bag or polyethylene bag. 25 kg supplied in multi-walled paper sack with polyethylene liner.


Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate


Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.


MARKETING AUTHORISATION HOLDER


Zoetis UK Limited

5th Floor, 6 St. Andrew Street

London

EC4A 3AE


MARKETING AUTHORISATION NUMBER


Vm 42058/4153


RENEWAL OF THE AUTHORISATION


Date:28 January 2002


DATE OF REVISION OF THE TEXT


Date:March 2014


26 March 2014

Page 5 of 5